← Back to Search

Janus Kinase (JAK) Inhibitor

Deucravacitinib for Ulcerative Colitis

Phase 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 292
Awards & highlights

Study Summary

This trial will assess the long-term safety and effectiveness of the drug Deucravacitinib in people who have already taken it for Crohn's disease or Ulcerative Colitis.

Eligible Conditions
  • Ulcerative Colitis
  • Crohn's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 292
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 292 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of AEs leading to study discontinuation
Number of adverse events (AEs)
Number of clinically significant abnormalities in clinical laboratory results: Clinical Chemistry test
+10 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Long-Term Extension Rollover Study: DeucravacitinibExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
2021
Completed Phase 4
~160

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,638 Previous Clinical Trials
4,128,447 Total Patients Enrolled
13 Trials studying Ulcerative Colitis
8,585 Patients Enrolled for Ulcerative Colitis

Media Library

Deucravacitinib (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04877990 — Phase 2
Ulcerative Colitis Research Study Groups: Long-Term Extension Rollover Study: Deucravacitinib
Ulcerative Colitis Clinical Trial 2023: Deucravacitinib Highlights & Side Effects. Trial Name: NCT04877990 — Phase 2
Deucravacitinib (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04877990 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Deucravacitinib been certified by the FDA?

"Data indicates that deucravacitinib has some evidence of safety, assigning it a score of 2. There is no existing data suggesting efficacy for this particular intervention."

Answered by AI

Does this experimental trial represent a pioneering venture?

"Since its inception in 2018, Deucravacitinib has gone through rigorous testing. Initially sponsored by Bristol-Myers Squibb and involving 240 individuals, the drug received Phase 2 approval following this initial trial. Today, 11 studies are actively recruiting participants across 401 cities and 36 countries worldwide."

Answered by AI

To what extent is participation being solicited for this research study?

"The sponsor of this experiment, Bristol-Myers Squibb, demands 300 qualified participants be present for the trial to take place. Potential volunteers can find two sites conducting it in Tyler Research Institute (Tyler, Texas) and University Of Pittsburgh Medical Center (Pittsburgh, Pennsylvania)."

Answered by AI

What other exploratory studies have been conducted with Deucravacitinib?

"Deucravacitinib was initially studied in 2018 by H-T. Centrum Medyczne Spolka z Ograniczona Odpowiedzialnoscia and has since accumulated 34 completed trials thus far. At present, 11 ongoing studies are taking place, with a particularly large concentration of them being conducted at Tyler, Texas."

Answered by AI

Are there any opportunities to participate in this investigation currently?

"Affirmative. Per the information stored on clinicaltrials.gov, this experiment is actively recruiting individuals as of now. It was originally posted online on May 7th 2021 and most recently updated on October 24th 2022; 300 people are needed to be enrolled from 15 distinct medical sites."

Answered by AI

How widely dispersed are the research institutions participating in this trial within the state?

"This clinical trial is currently taking place in 15 different cities, with Tyler, Pittsburgh and Richmond among them. For the convenience of participants, it is recommended that they select a location closest to them in order to reduce travelling demands."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
2021. "A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04877990.
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top